specific viral diagnosis in an individual patient and thus, they are unable to personalize the disease. Insensitive pointof-care diagnostics, the lack of a distinct clinical syndrome, and a broad epidemic curve that overlaps with influenza and other respiratory viruses all contribute to this lack of recognition of the problem. The development of new sensitive molecular diagnostics have dramatically altered epidemiologic research involving respiratory viruses, and recent studies now provide a more accurate picture of the burden of RSV disease [6, 7] . Yet, here too, the global community cannot personalize the problem to their own region or countries as most studies to date are from Europe and North America. Unless a disease is demonstrated in one's own backyard, there is a natural tendency to ignore or minimize the problem.
In this issue of Clinical Infectious Diseases, Lee and colleagues [8] present data from a large, 3-year study of adults hospitalized with respiratory illness in Hong Kong, China. In this study, the clinical and radiologic features of 607 adults with confirmed RSV infection are compared and contrasted to patients with seasonal influenza infection. The findings clearly demonstrate significant morbidity and mortality in older persons associated with RSV infection, which is comparable to influenza. RSV accounted for 6%-9% of respiratory illnesses during seasonal peaks; 72% of those admitted with RSV had lower respiratory tract complications, 11% required ventilatory support, and 9% died within 30 days. Similar to previous reports, infected patients were elderly (mean age, 75 years), and most had underlying medical conditions with chronic lung disease reported in 36%. Of note, although substantial proportions of both RSV and influenza patients had underlying medical conditions, RSV patients had significantly more lung disease and major systemic comorbidities. This observation may reflect the very large sample size of the current study allowing detection of more subtle differences in patient groups than previous reports. Importantly, there was no significant difference in the overall outcomes of survival and duration of hospitalization of RSV-and influenza-infected patients.
Although a number of the observations in this study are confirmatory, this confirmation is critical. The study by Lee et al was conducted in Asia, a region previously with little data on the incidence and impact of adult RSV disease. In a part of the world widely recognized as an epicenter for novel influenza and other respiratory viruses, the authors clearly show the importance of a well-known virus in a new age group. Although less likely to generate media frenzy than a new highly lethal pathogen, the importance of a virus that predictably sickens and kills significant numbers of older adults every year should not be underestimated. Given differences in cultures, household makeup, and environments, research that provides countryspecific data is extremely valuable in accurately defining the global impact of adult RSV. Chronic lung disease was demonstrated in the current study to be a significant risk factor for respiratory failure and death from RSV infection. Unfortunately, tobacco abuse remains a worldwide problem and all countries will have at-risk populations. In addition, as resource-poor nations develop improved healthcare and longer lifespans, the global burden of adult RSV disease will undoubtedly rise.
The strengths of this study include the large sample size, prospective diagnostic testing, a broad case definition not requiring fever, and comprehensive radiologic review. Several limitations, however, should be kept in mind when interpreting the findings of this study. Diagnosis of RSV was made by immunofluorescence staining of respiratory samples. Adults with RSV generally shed low titers of virus and it has been shown that antigen testing, whether by colorimetric assay or immunofluorescence, is relatively insensitive compared to molecular diagnostics and paired serology [9, 10] . Although the diagnostic tests used in this study do not invalidate the results, it should be noted that these findings may represent the "tip of the iceberg" in defining adult RSV disease in China. In addition, the RSV cases detected may have been biased toward patients with higher viral loads and more severe disease. A second limitation is that collection of clinical data by chart review rather than direct patient interview undoubtedly led to some bias in not recording symptoms such as nasal congestion and sore throat, which may be deemed unimportant to physicians caring for hospitalized patients. Last, the rates of bacterial complications should be interpreted with caution as it is unclear whether testing was standardized.
Several features of this study are unique and deserve further comment. The observed rates of fever (75%) and pneumonia (42%) in the current study by Lee and colleagues are higher than similar studies of hospitalized patients where rates of fever and pneumonia were 54%-61% and 20%-31%, respectively [4, 11, 12] . It is likely that different definitions of fever and pneumonia account for these observations. It is also possible that secondary bacterial infections may have been higher, yet, given the short period of symptoms prior to admission, this explanation seems unlikely. As noted previously, the use of immunofluorescence testing may have skewed detection to patients with higher viral loads either due to severity of illness or evaluation earlier in the course of illness. Future studies to determine if there are true regional differences in clinical features using polymerase chain reaction for detection should be considered.
The use of steroids was not associated with improvement in survival and was associated with longer hospital stays compared to those who did not receive steroids in the current study. Conclusions regarding the value of steroids should be cautious as this investigation was not a randomized clinical trial. However, these observations raise appropriate questions about the use of corticosteroids during acute viral infection. Animal models of RSV infection suggest that neither the use of antiviral agents nor the use of corticosteroids alone produces an optimal clinical outcome. Rather, the combination to reduce viral load plus an antiinflammatory agent may be the best approach [13] . Thus, if effective antiviral agents for RSV can be developed, it may be worth revisiting the question of corticosteroid use in the context of effective control of the virus.
Last, the observation that bacterial infections occurred in 12.5% of patients deserves further reflection. It is important to point out that establishing a bacterial diagnosis for respiratory infections is difficult under ideal circumstances and it is not clear how aggressively bacterial diagnosis was pursued in the current study. Despite these limitations, it is notable that 95% of RSV-infected patients received antibiotics, highlighting the global issue of antibiotic overuse. Given the current state of bacterial diagnostics, the best way to prevent antibiotic misuse with RSV infection may be development of an effective RSV vaccine.
In summary, the study by Lee and colleagues is one more important step toward convincingly establishing RSV as an important global adult pathogen. The data from this comprehensive study confirm age and chronic lung disease as major risk factors for severe RSV disease and provide useful information for future research targeting groups that would most benefit from vaccines and therapeutics.
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